Evidence map›Paper›PMID 39570439›Full record

ReviewMetabolic brain disease2024

Brain metabolic profiling of schizophrenia: a path towards a better understanding of the neuropathogenesis of psychosis.

Martina Rossetti, Stefano Stanca, Leona Bokulic Panichi, Paolo Bongioanni

Abstract readReview
PubMed Publisher
In one paragraph

Review in Metabolic brain disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Martina Rossetti *Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Savi 10, Pisa, 56126, Italy.ORCID 0009-0003-0770-8159
Stefano Stanca *Department of Humanities, University of Naples Federico II, Via Porta di Massa 1, Naples, 80133, Italy. stefano.stanca@unina.it.ORCID 0009-0002-9692-7347
Leona Bokulic PanichiNeuroCare Onlus, Pisa, 56100, Italy.ORCID 0009-0004-8331-3666
Paolo BongioanniNeuroCare Onlus, Pisa, 56100, Italy.ORCID 0000-0002-0767-1558

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia (SCZ) is a complex psychotic syndrome whose pathogenesis involves countless protagonists, none of which, to date, can fully explain how this disorder develops. In this narrative review, an overview of the biochemical impairment is offered according to several perspectives. Indeed, the metabolic framework behind SCZ dopaminergic hypotheses, glutamate - gamma-amynobutyric acid dysregulation, norepinephrine and serotonin, calcium channel dysfunction is addressed together with the energetic impairment, involving glucose and lipids in SCZ etiopathogenesis, in order to highlight the multilevel pathways affected in this neuropsychiatric disorder. Furthermore, neuroinflammation is analyzed, by virtue of its important role, widely investigated in recent years, in neurodegeneration. Tracing the neurotransmitter activity at the brain level by assessing the metabolic network behind the abovementioned molecules puts into light as unavoidable the need for future studies to adopt an integrate approach to address SCZ pathological and clinical picture. The combination of all these factors, essential in acquiring an overview on the complexity of SCZ pathophysiology represents a crucial step in the development of a more targeted management of SCZ patients.

Indexed as

BrainPsychotic DisordersSchizophreniaAnimalsHumansMental disorderMetabolitesNeurotransmittersPsychosisSchizophrenia

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.